For newbies...last quarter's update hints at possibilities.. Corporate Update
LumiSortTMCEO, Embro-Pantalony explained, "We have just passed the halfway point in the development of our LumiSortTM semen-sexing demonstration instrument. After a recent in-depth review of the project's status with our development partner, Lathrop Engineering, I am pleased to confirm that we are on track to complete the work this fall. We also continue to pursue patent protection for the many innovations that are being implemented during this phase of development. We look forward to having the opportunity to demonstrate to the industry later this year, the advantages of our LumiSortTM technology including speed, yield, and fertility.
VIRUSMAX®In July, Microbix filed a new complaint against Novartis, alleging infringement of its VIRUSMAX® patents in Europe. In January, Microbix successfully defended its European patents against a challenge by Novartis at the European Patent Office. Earlier this year, the Company filed a complaint against Novartis in Texas, alleging infringement of its U.S. VIRUSMAX® patents.
Embro-Pantalony stated, "We continue to work closely with our legal counsel in both the U.S. and Europe with respect to these actions. We are vigorously defending our VIRUSMAX® patent estate following our unequivocal success at the European Patent Office hearing last January."
Kinlytic®The Company has advanced its discussions with several parties that are interested in exploring potential partnerships to return Kinlytic® to the U.S. market. Embro-Pantalony commented, "I am very encouraged by the strong interest being expressed by these potential investors to return this life saving therapy to the market. I remain optimistic that we will ultimately secure a new partner to commercialize this drug."